← back to search

Ali A. Rizvi

University of Central Florida · US
Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Diabetes, Cardiovascular Risks, and Lipoproteins, Diabetes Management and Research, and Metabolism, Diabetes, and Cancer.
h-index
46
citations
6,944
works
226
NIH funding
primary concept
email

Recent publications

Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement
Frontiers in Endocrinology 2023cited by 30position: middledoi
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
International Journal of Molecular Sciences 2022cited by 69position: middledoi
Post-COVID syndrome, inflammation, and diabetes
Journal of Diabetes and its Complications 2022cited by 68position: firstdoi
Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets
The International Journal of Lower Extremity Wounds 2021cited by 66position: middledoi
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
International Journal of Molecular Sciences 2021cited by 55position: middledoi
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Expert Opinion on Drug Safety 2021cited by 53position: middledoi
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
Frontiers in Cardiovascular Medicine 2021cited by 48position: middledoi
The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart
International Journal of Molecular Sciences 2021cited by 43position: middledoi
Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
International Journal of Molecular Sciences 2021cited by 31position: firstdoi
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
Expert Opinion on Drug Safety 2021cited by 27position: middledoi
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2021cited by 26position: middledoi
Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
Metabolic Syndrome and Related Disorders 2020cited by 105position: middledoi
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
Diabetes Therapy 2020cited by 72position: middledoi
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Metabolism 2020cited by 69position: middledoi
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Journal of Clinical Medicine 2020cited by 60position: middledoi
Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
Metabolites 2020cited by 57position: middledoi
Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
Metabolites 2020cited by 51position: middledoi
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
Metabolism 2020cited by 42position: lastdoi
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights
Journal of Cardiovascular Pharmacology and Therapeutics 2020cited by 32position: middledoi
Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
Metabolites 2020cited by 31position: middledoi
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018cited by 145position: middledoi
Bad Phages in Good Bacteria: Role of the Mysterious orf63 of λ and Shiga Toxin-Converting Φ24B Bacteriophages
Frontiers in Microbiology 2017cited by 20position: middledoi
Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
Frontiers in Pharmacology 2016cited by 131position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Manfredi Rizzo · University of South Carolina19 papers (2016–2022)Anca Pantea Stoian · University of South Carolina18 papers (2020–2022) · 10 papers (2016–2021) · 9 papers (2016–2021)Yajnavalka Banerjee · University of Dundee9 papers (2020–2022) · 8 papers (2016–2021)Νικόλαος Παπάνας · University Hospital of Alexandroupolis7 papers (2020–2022)Peter P. Tóth · University of Debrecen6 papers (2016–2022)Giuseppe Montalto · AbbVie (United States)6 papers (2016–2020)Maciej Banach · University of Southampton5 papers (2020–2022)Khalid Al‐Rasadi · Sultan Qaboos University Hospital4 papers (2021–2022)Francesco Cosentino · Linköping University4 papers (2018–2022) · 4 papers (2021–2022) · 4 papers (2021–2022) · 3 papers (2021–2022) · 3 papers (2021–2022)Antonio Ceriello · Telekom Austria3 papers (2021–2022) · 3 papers (2020–2021) · 3 papers (2020–2021) · 3 papers (2021–2022)